Skip to main content

PositiveSPX4,060.431.10%Positive
PositiveIXIC11,512.411.76%Positive
PositiveDJI33,949.410.61%Positive
PositiveSTOXX453.980.42%Positive
PositiveFTSE7,761.110.21%Positive
PositiveN22527,381.180.07%Positive

GRAL.O

GRAL.O

Official Data Partner

Latest Trade: trading higher--
Change; --; --

As of Jan 27 2023. Values delayed up to 15 minutes

Day Range: -- - --
52-Week Range: -- - --

About (GRAL.O)

Company Information

GRAIL Inc is a United States-based healthcare company. The Company focuses on developing new technologies for early cancer detection. By leveraging it's platform technology, the Company has developed a multi-cancer early detection blood test that has the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal from a single blood draw. The Company has developed multi-cancer early detection test, Galleri, which is designed as a screening test for asymptomatic individuals over 50 years of age. In addition to Galleri, the Company is utilizing it's technology platform and population-scale studies to introduce a diagnostic aid for cancer test (DAC). DAC is designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing a minimal residual disease (MRD) test, designed to enable blood-based detection with or without tissue.

Address

1525 O'Brien Drive
MENLO PARK, CA
94025
United States

Contact Information

+1 (650) 7719796

https://grail.com/

Industry

Biotechnology & Drugs

Latest News

MarketscategoryExclusive: Illumina to face EU fine of 10% of turnover over Grail deal -sources, article with galleryJanuary 11, 2023
MarketscategoryIllumina challenges EU order to keep Grail separate, article with imageJanuary 10, 2023
MarketscategoryAnalysis: Dealmakers grapple with unprecedented U.S. challenge to mergers, article with imageDecember 27, 2022
FOCUSCancer researchers question antitrust arguments against Illumina-Grail deal, article with galleryDecember 16, 2022
BusinesscategoryGuardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 35%
Guardant Health Inc said on Thursday a pivotal trial of its DNA blood test showed it detected 83% of colorectal cancers and 13% of advanced adenomas, a cancer precursor, but the results fell short of a rival stool-based test, sending the company's shares sharply lower.
December 16, 2022
MarketscategoryIllumina defends $7.1 bln Grail buy to fend off antitrust regulators, article with imageDecember 14, 2022
MarketscategoryEU charge sheet tells Illumina to swiftly unwind Grail deal, article with imageDecember 5, 2022
BusinesscategoryIllumina cuts 5% of its workforce, article with imageNovember 14, 2022

Financials

Income Statement

Millions ()	2019	2018
	0	0	0
	0	0	0
Net Income	-244.855	-275.718	0

2019 (millions )

Income Statement table

Balance Sheet

Millions ()	2019	2018
Total Assets	635.519	686.845	0
Total Debt	0	0.8	0
Total Liabilities	84.992	86.473	0

2019 (millions )

Balance Sheet table

Cash Flow

Millions ()	2019	2018
Cash from Operating Activities	-245.794	-209.26	0
Financing Cash Flow Items	-0.932	0	0
Cash from Investing Activities	133.037	-93.39	0

2019 (millions )

Cash Flow table

Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes

Markets Performance

Official Data Partner

Commodities

Future	Last	% Change
Gold	1,929.10	--
Copper	792.80	--
Brent Crude Oil	87.67	0.23%Positive
CBOT Soybeans	1,523.00	0.03%Negative

Currencies

Exchange	Last	% Change
EUR/USD	1.0883	0.01%Positive
GBP/USD	1.2400	0.05%Negative
JPYUSD=X	129.7000	0.39%Negative
CNYUSD=X	6.7825	--

Rates & Bonds

Name	Yield	Change
US 10Y	3.509	+0.018
DE 10Y	2.214	--
UK 10Y	3.312	-0.006
JP 10Y	0.479	+0.019

Stocks

Index	Last	% Change
S&P 500	4,060.43	1.10%Positive
Euro STOXX 50	4,173.98	0.62%Positive
FTSE 100	7,761.11	0.21%Positive
Nikkei 225	27,381.18	0.07%Positive

Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes